News & Media
Press Releases
Amolyt Pharma Strengthens Leadership Team with Appointment of Mark Sumeray, M.D., as Chief Medical Officer
June 29, 2022
Download a PDF copy of this press release: EN FR Industry veteran brings over two decades of global experience in pharmaceutical, medical devices and biotech …
Amolyt Pharma Announces Positive Results from First Patient Cohort of Phase 2a Trial of AZP-3601 for the Treatment of Hypoparathyroidism
June 1, 2022
Download a PDF copy of this press release: EN FR Four abstracts accepted as poster presentations for the Endocrine Society’s Annual Meeting LYON, France, and …
Amolyt Pharma Announces Abstracts Accepted for Presentation at ECE and ENDO
May 16, 2022
Download a PDF copy of this press release: EN FR LYON, France, and Cambridge, MA, May 16, 2022 — Amolyt Pharma, a global company specialized …
Presentations
- All PRESENTATIONS
- AZP-3813
- AZP-3601
All PRESENTATIONS
- All PRESENTATIONS
- AZP-3813
- AZP-3601
AZP-3601
Living With an “Invisible Disease”: A Qualitative Study With Patients With Hypoparathyroidism
Written by
Dan Hennings
AZP-3601
Healthcare Resource Utilization Burden of Patients with Hypoparathyroidism in the United States
Written by
walid
Upcoming events
Hypopara Awareness Day
Date: June 1, 2022
ENDO 2022 – Annual Meeting of the Endocrine Society
Date: June 10 – June 14, 2022 (Atlanta, Georgia)
ASBMR 2022 Annual Meeting
Date: September 9 - 12, 2022 (Austin, TX)
Social Updates
TWITTER
We are pleased to announce the addition of Mark Sumeray, M.D. to our team as #CMO. Dr. Sumeray bring...
Read More »We're looking forward to joining other leaders in the #endocrine space at #ENDO2022. Our oral presen...
Read More »Our #CEO, Dr. Thierry Abribat, was featured in a recent @Pharmashot interview discussing the investi...
Read More »